Propanc Biopharma, Inc. (PPCB)

Name: Propanc Biopharma, Inc. (PPCB) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Propanc Biopharma, Inc. (PPCB)

Stock Card

$1.01

$-0.01 (-0.98%)

As on 04-Sep-2026 16:16EDT

Market cap

$2 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.3

Div. Yield

0 %

Propanc Biopharma, Inc. (PPCB) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.97 High: 1.05

52 Week Range

Low: 0.95 High: 65.00

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

2.9
Debt to Equity

0
Book Value

$11.2
EPS

$-13.6
Face value

--
Shares outstanding

2,278,371

Years Aggregate

CFO

$--

EBITDA

$--

Net Profit

$--

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Propanc Biopharma, Inc. (PPCB)	-92.5	-3.8	-38.2	-98.4	-96.8	-96.7	-41.1
BSE Sensex^*	-10.0	-3.5	2.6	-5.6	5.0	5.5	10.2
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 04-Sep-2026 | *As on 07-Sep-2026 | #As on 26-Oct-2023

The underlying data is unavailable.

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Propanc Biopharma, Inc. (PPCB)	1.0	2.3	0.0	-18.4	-59,201.2	-151.8	0	0.3
Arrowhead Pharmaceuticals (ARWR)	86.3	12,161.6	669.5	-320.0	-0.8	-71.1	--	26.2
Ascendis Pharma A/S - ADR	270.6	17,746.8	1,054.4	755.9	5.7	--	20.9	10.5
Cytokinetics Inc (CYTK)	72.7	10,109.8	71.0	-894.0	-1,175.8	--	--	60.5
Exelixis (EXEL)	59.0	14,621.6	2,435.9	860.6	31.0	43	18.6	7.9
Halozyme Therapeutics (HALO)	110.2	12,506.3	1,663.7	413.6	36.3	430	32.3	86.7
Krystal Biotech (KRYS)	358.2	10,603.5	440.5	241.5	33.4	18.7	44.9	8.1
Madrigal Pharmaceuticals (MDGL)	541.1	12,501.2	1,283.9	-325.1	-19.0	-57.7	--	23.9
Medpace Holdings (MEDP)	591.3	16,503.9	2,782.3	491.5	21.1	110.1	34.7	38.2
Nuvalent Inc (NUVL)	124.0	9,808.7	0.0	-450.1	--	-44.6	--	8.4

Shareholding Pattern

View Details

About Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an... intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia. Read more

CEO & Executive Chairman

Mr. James Nathanielsz
Chief Financial Officer

Ms. Jeannine Zimmerman
Headquarters

Camberwell, VIC
Website

https://www.propanc.com

FAQs for Propanc Biopharma, Inc. (PPCB)

What is the current share price of Propanc Biopharma, Inc (PPCB) Today?

The share price of Propanc Biopharma, Inc (PPCB) is $1.01 (NASDAQ) as of 04-Sep-2026 16:16 EDT. Propanc Biopharma, Inc (PPCB) has given a return of -96.85% in the last 3 years.

What is the current PB & PE ratio of Propanc Biopharma, Inc (PPCB)?

Since, TTM earnings of Propanc Biopharma, Inc (PPCB) is negative, P/E ratio is not available.
The P/B ratio of Propanc Biopharma, Inc (PPCB) is 0.26 times as on 04-Sep-2026, a 95 discount to its peers’ median range of 5.33 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-0.82	3.47
2024	-0.16	-0.08
2023	-9,179.09	-7,835.79
2022	-9,141.88	-8,036.35
2021	-6,959.53	-4,596.47

What is the 52 Week High and Low of Propanc Biopharma, Inc (PPCB)?

The 52-week high and low of Propanc Biopharma, Inc (PPCB) are Rs 65.00 and Rs 0.95 as of 07-Sep-2026.

What is the market cap of Propanc Biopharma, Inc (PPCB)?

Propanc Biopharma, Inc (PPCB) has a market capitalisation of $ 2 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Propanc Biopharma, Inc (PPCB)?

Before investing in Propanc Biopharma, Inc (PPCB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.